Johnson & Johnson reported strong Q1 earnings with increased sales, EPS, and raised guidance, which are positive indicators. However, the temporary pause in their COVID-19 vaccine rollout due to safety concerns introduces short-term uncertainty. Overall, the solid financial performance likely outweighs the vaccine-related hesitation in the immediate term.

[1]